Netris Pharma’s lead product was awarded €1.2 million Eurostar grant to make an antibody therapeutic to treat arthritis and metastatic bone cancer pain.
The drug, intended for adult patients with moderate-to-severe systemic lupus erythematosus, is the only new therapy approved for SLE in more than a decade.
Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.
Aiming to facilitate and accelerate discovery of biologics, Aridis’ Apex platform can also discover antibodies against viruses ‘within one day of a pandemic’.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.
Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.
Fusion Antibodies signed an agreement with Analytics Engines to bring machine learning and AI to its humanization platform in an aim to bolster product quality and manufacturability.
Shark antibodies are an attractive way to deliver biologics to the brain, says Ossianix which is using its blood-brain barrier (BBB) crossing technology in collaboration with Lundbeck.
The US FDA says draft guidelines on risk-based immunogenicity testing of protein drugs will encourage the pharma industry to continue development efforts.
The life sciences company, ForteBio, has launched its Dip and Read Protein G biosensor, designed for the fast-track analysis of specific biomolecular interactions of various types of the antibody molecule, mammalian immunoglobulin.
Concerns about the quality and capabilities of Baxter’s manufacturing operations have led to Halozyme issuing a notice of breach and stating it may terminate their Hylenex relationship.
Thermo Fisher Scientific has followed up its acquisition of Open Biosystems with the purchase of antibody experts Affinity BioReagents to further bolster its protein research offering.
The PER.C6 cell culture-based antibody production platform has
achieved a new record yield of 27 grams of IgG antibody per litre,
bettering the 15 gram per litre mark that was reported earlier in
the year.
Life sciences equipment company Millipore says its new protein
detection system, SNAP i.d, can improve the time it takes to carry
out Western blots by as much as 80 per cent compared to
conventional immunodetection methods.
Sanofi-Aventis recently admitted it needed to increase the number
of biotech compounds in its pipeline and now, true to its word, the
French pharma heavyweight has signed a big antibody deal with US
biotech Regeneron.
Ablynx, a biopharma firm that specialises the potentially lucrative
sector of miniature antibodies, has announced it plans to launch on
the stock market this year.
German firm Biotest has bought up Nabi Biopharmaceuticals biologics
division in a multi-million Euro deal, less than three months after
the unit was created following Nabi restructuring efforts.
Ablynx, one of the two main players in the miniature antibody
sector, has signed 'by far' the biggest deal in its history, to
help Boehringer Ingelheim develop up to ten so called 'Nanobodies'.
An award-winning therapeutic protein technology, touted as superior
to antibodies, has attracted venture capitalist investment for its
owners, the Swiss biotech Molecular Partners.
Belgian biopharma Ablynx has announced its lead miniature antibody
has shown good interim results in a first-in-man trial, leaving it
one step ahead of GlaxoSmithKline (GSK).
GlaxoSmithKline (GSK) outlined more details on the mechanism of its
anticancer drug ofatumumab - an antibody that was the subject of
the biggest ever pharma licensing deal.
The seventh in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Researchers in Belgium have succeeded in using plant seeds to
produce high yields of proteins that bear a strong resemblance to
human antibodies, thus bringing the possibility of using plant
systems as an inexpensive alternative to...
Wyeth Pharmaceuticals has announced they have entered into
collaboration with Ablynx in a deal, which aims to commercialise a
class of antibody-derived therapeutic proteins targeting diseases
that include oncology and Alzheimer's...
